Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
23-SEP-2024 | 6,938.9 | 6,974.95 | 6,721.8 | 6,748.1 | 2,272 | 5,40,31,170.5 | 3,136 |
24-SEP-2024 | 6,900 | 8,040 | 6,851.3 | 7,878.25 | 1,62,007 | 12,10,77,67,152.1 | 54,782 |
25-SEP-2024 | 7,635.05 | 7,777.6 | 7,465.75 | 7,528.85 | 41,264 | 2,69,76,17,634.45 | 22,304 |
26-SEP-2024 | 7,533 | 7,533 | 7,301 | 7,340.65 | 7,598 | 34,28,70,757.05 | 9,137 |
27-SEP-2024 | 7,300 | 7,355.8 | 7,155.55 | 7,185.6 | 7,451 | 26,62,06,347.1 | 7,393 |
30-SEP-2024 | 7,150 | 8,137.5 | 7,125.05 | 7,970.05 | 1,51,013 | 9,37,48,15,098.6 | 31,716 |
01-OCT-2024 | 7,735.05 | 7,925 | 7,685 | 7,734.5 | 22,378 | 1,18,98,48,325.8 | 10,608 |
03-OCT-2024 | 7,690 | 7,880 | 7,514.95 | 7,636.75 | 21,665 | 83,60,09,776.9 | 9,483 |
04-OCT-2024 | 7,636.55 | 7,699.9 | 7,374.9 | 7,436.7 | 12,515 | 42,19,30,226.1 | 7,963 |
07-OCT-2024 | 7,442.65 | 8,139 | 7,440 | 7,845.55 | 1,54,393 | 8,81,36,03,828.8 | 37,877 |
08-OCT-2024 | 7,700 | 7,935 | 7,661.9 | 7,784.6 | 29,162 | 1,19,52,95,615.25 | 14,510 |
09-OCT-2024 | 7,859.9 | 8,094 | 7,802 | 7,880.65 | 17,079 | 71,45,84,759.75 | 10,383 |
10-OCT-2024 | 7,879.85 | 7,880.65 | 7,704 | 7,739.7 | 7,945 | 24,83,88,760.7 | 7,386 |
11-OCT-2024 | 7,789.95 | 7,951 | 7,722.1 | 7,789.2 | 12,400 | 47,31,69,232.75 | 5,993 |
14-OCT-2024 | 7,800 | 7,914.95 | 7,613 | 7,697.45 | 10,297 | 32,28,27,651.15 | 9,605 |
15-OCT-2024 | 7,778.3 | 7,778.3 | 7,575 | 7,615.95 | 6,107 | 19,20,49,079.1 | 5,185 |
16-OCT-2024 | 7,661.65 | 7,820 | 7,592.05 | 7,649.75 | 8,917 | 26,96,48,934.15 | 4,803 |
17-OCT-2024 | 7,649.75 | 7,773.85 | 7,520.85 | 7,627.45 | 6,154 | 16,84,55,168.1 | 4,651 |
18-OCT-2024 | 7,642.95 | 7,659.95 | 7,306.05 | 7,520.3 | 8,445 | 25,27,14,526.85 | 7,047 |
21-OCT-2024 | 7,550 | 7,550 | 7,311.5 | 7,392.15 | 5,883 | 14,96,10,443.15 | 6,090 |
22-OCT-2024 | 7,421 | 7,421 | 7,170.2 | 7,190.6 | 4,415 | 12,61,49,057.15 | 6,172 |
The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.
The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.
Here are some of the stocks that may see significant price movement today: Punjab National Bank, NTPC, Power Grid, etc.
The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
